The global bone regeneration market is poised for remarkable growth, with projections estimating its value to surge from USD 5,380.75 million in 2023 to USD 7,827.8 million by 2033. This growth is ...

Cell therapy development for Parkinson’s disease has been a marathon. Two new papers represent an important step forward.

Both studies, which are reporting the results of early-stage clinical trials, show that the interventions were safe, and that ...

Introduction NurExone (TSXV:NRX) an innovative Canadian biopharmaceutical company, has reached a significant milestone in its efforts to revolutionize spinal cord injury treatments. The company ...

Because RNAs are so central to our biology, they are also drivers of a wide array of diseases. Defects in how RNA is produced ...

The global biobanking market was valued at $37.93 billion in 2019, and is estimated to reach $57.67 billion by 2027, growing at a CAGR of 4.6% from 2020 to 2027. Rise in funding by private & ...

BioLife Solutions is poised to benefit from the booming cell and gene therapy sector. Read more to see my investment strategy ...

All patients provided written informed consent for the procedure based on the requirements for class III regenerative medicine under the Japanese Act on the Safety of Regenerative Medicine. This study ...

To build resilient organizations that can weather the future, leaders must embrace regenerative leadership. This requires shifting from exploitative business models that prioritize efficiency to ...

Opinions expressed are those of the author. In an era where healthcare is becoming increasingly transactional and impersonal, I see concierge medicine emerging as a solution to this broken system.

Positive predictive value was higher with MELD Graph compared with existing baseline algorithm. HealthDay News — A graph neural network using data from the Multicenter Epilepsy Lesion Detection ...

As the chief executive officer of the nonprofit multistakeholder advocacy organization the Alliance for Regenerative Medicine, I hear all the questions: Will the technology meet the promise?